Royal Bank Of Canada Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $130.00

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price objective reduced by Royal Bank Of Canada from $140.00 to $130.00 in a report released on Tuesday,Benzinga reports. They currently have an outperform rating on the stock.

Other research analysts also recently issued research reports about the stock. The Goldman Sachs Group upped their target price on shares of Rhythm Pharmaceuticals from $141.00 to $157.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Guggenheim boosted their price objective on shares of Rhythm Pharmaceuticals from $140.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, February 27th. HC Wainwright cut their target price on Rhythm Pharmaceuticals from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Monday, March 2nd. TD Cowen reissued a “buy” rating on shares of Rhythm Pharmaceuticals in a report on Thursday, December 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $131.13.

Rhythm Pharmaceuticals Trading Up 5.2%

NASDAQ RYTM opened at $90.31 on Tuesday. Rhythm Pharmaceuticals has a 12 month low of $45.90 and a 12 month high of $122.20. The stock has a market cap of $6.17 billion, a P/E ratio of -29.04 and a beta of 2.06. The stock’s fifty day moving average price is $99.31 and its 200-day moving average price is $102.60.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.06. The firm had revenue of $57.25 million during the quarter, compared to analyst estimates of $56.16 million. Rhythm Pharmaceuticals had a negative return on equity of 266.56% and a negative net margin of 103.57%.Rhythm Pharmaceuticals’s quarterly revenue was up 36.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.72) EPS. As a group, analysts forecast that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Rhythm Pharmaceuticals news, CFO Hunter C. Smith sold 4,385 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $101.26, for a total transaction of $444,025.10. Following the completion of the sale, the chief financial officer directly owned 110,512 shares in the company, valued at approximately $11,190,445.12. The trade was a 3.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Christopher Paul German sold 5,614 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total value of $502,789.84. Following the transaction, the chief accounting officer directly owned 160 shares in the company, valued at $14,329.60. The trade was a 97.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 27,267 shares of company stock valued at $2,719,955. 6.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC increased its position in shares of Rhythm Pharmaceuticals by 956.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 13,254 shares of the company’s stock valued at $1,339,000 after purchasing an additional 12,000 shares during the last quarter. EFG Asset Management North America Corp. purchased a new position in shares of Rhythm Pharmaceuticals in the third quarter worth approximately $2,047,000. Penserra Capital Management LLC purchased a new position in shares of Rhythm Pharmaceuticals in the third quarter worth approximately $3,073,000. Hillsdale Investment Management Inc. bought a new stake in Rhythm Pharmaceuticals during the third quarter valued at approximately $4,302,000. Finally, Norges Bank purchased a new stake in Rhythm Pharmaceuticals during the second quarter valued at approximately $13,105,000.

Rhythm Pharmaceuticals News Roundup

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: FDA approval for a new indication — The FDA approved IMCIVREE® (setmelanotide) for patients with acquired hypothalamic obesity, making it the first and only approved therapy for this rare, difficult‑to‑treat condition; this expands the commercial opportunity and is the primary catalyst for the stock rally today. FDA Approval Release
• Positive Sentiment: Some broker price targets remain elevated — An American Banking News aggregation shows broker price targets (one cited at $133.19), which supports upside narratives among buy‑side holders. Broker PT Coverage
• Neutral Sentiment: HC Wainwright trims price target but keeps a Buy — HC Wainwright lowered its PT to $100 (from $110) and continues to rate RYTM a Buy, which tempers the bullish view though still implying upside from current levels. Coverage Note
• Neutral Sentiment: Valuation commentary after share weakness — Coverage pieces are reassessing valuation given recent volatility and long‑term returns; useful context for investors thinking about entry points. Valuation Article
• Negative Sentiment: Late‑stage trial failure for a lead indication — Rhythm reported a late‑stage weight‑loss trial setback for IMCIVREE in certain rare obesity populations, a development that previously drove shares lower and raises questions about broader label expansion and near‑term upside. Trial Failure Report
• Negative Sentiment: Multiple firms issue pessimistic forecasts / lower expectations — Bank of America and RBC published negative outlooks, and Citizens JMP and Needham also lowered expectations; these analyst moves increase downward pressure and suggest elevated near‑term volatility. Bank of America Forecast RBC Forecast Citizens JMP Needham
• Negative Sentiment: HC Wainwright lowered near‑term EPS estimate — The firm reduced its Q3 2027 EPS forecast (to $0.33 from $0.42), signaling tempered near‑term revenue/earnings visibility despite the approval and ongoing commercialization work.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.